Atriva‘s Approach to a de-risked and rapid Development
ATRIVA focuses on repurposing existing so-called MEK-inhibitors, originally used in oncology, which are already marketed or have undergone clinical investigations.
ATRIVA scientists are leading experts for influenza viruses. They found that virus replication is dependent on a specific cellular pathway, which can be effectively blocked by MEK-inhibitors.
MEK-inhibitors have a larger therapeutic time window than existing anti-influenza drugs without inducing resistance (compared to Tamiflu) and suppress dangerous bacterial co-infections of the lungs as proven in extensive pre-clinical studies of ATRIVA scientists. The risk of side effects is negligible, due to short therapeutic intervention of 5 to maximal 7 days.